Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

The FDA has granted fast track designation to amezalpat for the treatment of patients with hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) is an aggressive disease that accounts for 80%-90% of all primary liver cancers. Previous findings have shown fibroblast growth factor 19 (FGF-19) to be overexpressed in ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Investigator Award has been awarded to two surgeon-scientists at the National Cancer Centre Singapore (NCCS) to pursue novel research in liver cancer and head and neck cancers. Globally, liver cancer ...

A new study reveals that even low-dose, chronic exposure to air pollution can trigger liver inflammation, fibrosis, and metabolic disruptions, increasing the risk of fatty liver disease and other ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

In the ALEXANDRA/IMpassion030 trial, Tecentriq (atezolizumab) added to postoperative chemotherapy was not found to improve ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the CD19-directed CAR T cell therapy, which is already approved in the EU for certain lymphomas, be authorised to treat ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...